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Abstract 
Introduction 
Individuals carrying pathogenic mutations in BRCA1/2 genes have a high lifetime risk of 
breast cancer. BRCA1 and BRCA2 are involved in DNA double strand break repair, DNA 
alterations that can be caused by exposure to reactive oxygen species, a main source of which 
are mitochondria. Mitochondrial genome variations affect electron transport chain efficiency 
and reactive oxygen species production. Individuals from different mitochondrial 
haplogroups differ in their metabolism and sensitivity to oxidative stress. Variability in 
mitochondrial genetic background can alter reactive oxygen species production, leading to 
cancer risk. Here we test the hypothesis that mitochondrial haplogroups modify breast cancer 
risk in BRCA1/2 mutation carriers. 
Methods 
We genotyped 22214 (11421 affected, 10793 unaffected) mutation carriers belonging to the 
Consortium of Investigators of Modifiers of BRCA1/2 for 129 mitochondrial polymorphisms 
using the iCOGS array. Haplogroup inference and association detection were performed 
using a phylogenetic approach. ALTree was applied to explore the reference mitochondrial 
evolutionary tree and detect subclades enriched for affected or unaffected individuals. 
Results 
We discovered that subclade T1a1 was depleted in affected BRCA2 mutation carriers than the 
rest of clade T, (Hazard Ratio (HR) = 0.55 (95% Confidence Interval (CI) 0.34-0.88, p-value 
= 0.01). Compared with the most frequent haplogroup in the general population i.e. H and T 
clade, the T1a1 haplogroup has an HR = 0.62 (95% CI = 0.40-0.95, p-value = 0.03). We also 
identified three potential susceptibility loci, including G13708A/rs28359178, which has 
demonstrated an inverse association with familial breast cancer risk. 
Conclusions 
This study illustrates how original approaches like the phylogeny-based method we used can 
empower classical molecular epidemiological studies aimed at identifying association or risk 
modification effects. 
Introduction 
Breast cancer is a multifactorial disease, with genetic, life-style and environmental 
susceptibility factors. Approximately 15-20% of the familial aggregation of breast cancer is 
accounted for by mutations in high-penetrance susceptibility genes [1-3] such as BRCA1, 
BRCA2. Pathogenic mutations in BRCA1 and BRCA2 confer lifetime breast cancer risk of 
60%-85% [4,5] and 40%-85% [4,5], respectively. Other genomic variations (for example in 
genes encoding proteins interacting with BRCA1 and BRCA2) have been identified as 
modifiers of breast cancer risk and increase or decrease the risk initially conferred by BRCA1 
or BRCA2 mutation [6]. 
BRCA1 and BRCA2 are involved in DNA repair mechanisms, including double-strand break 
(DSB) repair by homologous recombination [7,8]. DSB are considered to be one of the most 
deleterious forms of DNA damage because the integrity of both DNA strands is compromised 
simultaneously. These breaks can lead to genomic instability resulting in translocations, 
deletions, duplications, or mutations when not correctly repaired [9]. Reactive Oxygen 
Species (ROS) are one of the main causes of DSBs, along with exposure to ionizing 
radiation, various chemical agents, and ultraviolet light [10]. 
ROS are naturally occurring chemical derivative of metabolism. Elevated levels of ROS and 
down-regulation of ROS scavengers and/or antioxidant enzymes can lead to oxidative stress, 
which is associated with a number of human diseases, including various cancers [11]. The 
electron transport chain process, which takes place in the mitochondria, generates the 
majority of ROS in human cells. Variations in the mitochondrial genome have been shown to 
be associated with metabolic phenotypes and oxidative stress markers [12]. Mitochondrial 
dysfunction recently was shown to promote breast cancer cell migration and invasion through 
the accumulation of a transcription factor HIF1α via increased production of reactive oxygen 
species [13]. 
The human mitochondrial genome (mtDNA) has undergone a large number of mutations that 
have segregated during evolution. Those changes are now used to define mitochondrial 
haplogroups. Some of these changes slightly modify metabolic performance and energy 
production; thus, all haplogroups do not have identical metabolic capacities [14]. It has been 
hypothesized that the geographic distribution of mitochondrial haplogroups results from 
selection of metabolic capacities mainly driven by adaptation to climate and nutrition [15,16]. 
Mitochondrial haplogroups have been associated with diverse multifactorial diseases, such as 
Alzheimer’s disease [17], hypertrophic cardiomyopathy [18], retinal diseases [19] or age-
related macular degeneration [20]. Variations in mtDNA have also been linked to several 
types of cancer, such as gastric cancer [21] or renal cell carcinoma [22]. Interestingly, 
variations in mtDNA have been linked to several types of female cancers: endometrial [23], 
ovarian [24], and breast cancer [25,26]. A recent study underlined the possibility that 
mitochondrial genome might be involved into the pathogenic and molecular mechanism of 
familial breast cancer [27]. 
The Collaborative Oncological Gene-environment Study [28] (COGS) is a European project 
designed to improve understanding of genetic susceptibility to breast, ovarian and prostate 
cancer. This project involves several consortia, the Breast Cancer Association Consortium 
(BCAC) [29], the Ovarian Cancer Association Consortium (OCAC) [30], the Prostate Cancer 
Association Group to Investigate Cancer Associated Alterations in the Genome 
(PRACTICAL) [31], and the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) 
[32]. CIMBA is a collaborative group of researchers working on genetic modifiers of cancer 
risk in BRCA1 and BRCA2 mutation carriers. As part of the COGS project, more than 
200,000 single nucleotide polymorphisms (SNPs) were genotyped for BRCA1 and BRCA2 
female mutation carriers on the iCOGS chip, including 129 mitochondrial polymorphisms. 
The iCOGS chip is a custom Illumina™ Infinium genotyping array, designed to test, in a 
cost-effective manner, genetic variants related to breast, ovarian and prostate cancers. 
In this study, we explored mitochondrial haplogroups as potential modifiers of breast cancer 
risk in women carrying pathogenic BRCA1 or BRCA2 mutations. Our study includes females 
diagnosed with breast cancer and unaffected carriers belonging to the CIMBA. We used an 
original analytic phylogenetic-based approach implemented in a homemade algorithm and in 
the program ALTree to infer haplogroups and to detect associations between haplogroups and 
breast cancer risk. 
Methods 
Ethics statement 
An informed written consent was obtained from all participants. All contributing studies 
involved in CIMBA received approvals from institutional review committees at their host 
institutions. Ethical committees that approved access to the data analyzed in this study are 
listed in Additional file 1. 
BRCA1 and BRCA2 mutation carriers 
Final analyses included 7,432 breast cancer cases and 7,104 unaffected BRCA1 mutation 
carriers, and 3,989 invasive breast cancer and 3,689 unaffected BRCA2 mutation carriers, all 
belonging to the CIMBA consortium. Supplementary specifications regarding inclusion 
profiles and studies belonging to CIMBA are available in Couch et al. [33] and Gaudet et al. 
[34]. All analyses were conducted separately on CIMBA BRCA1 and BRCA2 mutation 
carriers (abbreviated pop1 and pop2, respectively). Eligible female carriers were aged 18 
years or older and had a pathogenic mutation in BRCA1 and/or BRCA2. Women mutated on 
both BRCA1 and BRCA2 were included in downstream analyses. Data were available on year 
of birth, age at study recruitment, age at cancer diagnosis, BRCA1 and BRCA2 mutation 
description, and self-reported ethnicity. Women with ovarian cancer history were not 
excluded from analyses, and represent 15% and 7% of BRCA1 and BRCA2 mutation carriers 
respectively. Information regarding mastectomy was incomplete, and was therefore not used 
as an inclusion/exclusion parameter. 
Genotyping and quality filtering 
Genotyping was conducted using the iCOGS custom Illumina Infinium array. Data from this 
array are available to the scientific community upon request, please see [35] for more 
information. Genotypes were called using Illumina’s proprietary GenCall algorithm. 
Genotyping and quality filtering were described previously [33,34]. Initially, 129 
mitochondrial SNPs were genotyped for both BRCA1 and BRCA2 mutation carriers. SNPs 
fulfilling the following criteria were excluded from downstream analyses: monoallelic SNPs 
(minor allele frequency equals 0), SNPs with more than 5% data missing, annotated as 
triallelic, or having probes cross-matching with the nuclear genome. Heterozygous genotypes 
were removed from analyses, and we further filtered out SNPs having more than 5% of 
heterozygous calls, to limit potential for heteroplasmy affecting our results. We also did not 
retain SNPs representing private mutations. These mutations are rare, often restricted to a few 
families, and not sufficiently prevalent in the general population to be included in the 
reference mitochondrial evolutionary tree (see below). This last step of filtration yielded 93 
and 92 SNPs for the pop1 and pop2 analyses, respectively (see Additional file 2). Only 
individuals with fully defined haplotypes, i.e. non-missing genotypes for the 93 and 92 SNPs 
selected for pop1 and pop2 respectively were included in downstream analyses (14,536 and 
7,678 individuals respectively). 
Mitochondrial genome evolution and haplogroup definition 
Analyses were based on the theoretical reconstructed phylogenetic tree of the mitochondrial 
genome (mtTree) known as PhyloTree [36] (v.15). The mtTree is rooted by the 
Reconstructed Sapiens Reference Sequence (RSRS). RSRS has been identified as the most 
likely candidate to root the mtTree by refining human mitochondrial phylogeny by parsimony 
[37]. Each haplogroup in mtTree is defined by the set of mitochondrial genome SNPs that 
have segregated in RSRS until today in the mitochondrial genome. Each haplogroup is fully 
characterized by the 16569 bp sequence resulting from the application of all the substitutions 
that are encoded by the corresponding SNPs in RSRS sequence. 
Haplogroups imputation 
The phylogenetic approach used to infer haplogroups is described in Figure 1. Mitochondrial 
genome sequences can be reconstructed at each node of mtTree, given the substitutions that 
have segregated in RSRS. Each haplogroup therefore has a corresponding full-length 
mitochondrial sequence. However, the full-length mitochondrial sequence is not available in 
the data, since the iCOGs platform captured only 93 and 92 SNPs for pop1 and pop2 
respectively. Thus, for each of the 7864 nodes of the phylogenetic tree, the corresponding 
short haplotype, i.e. the full-length sequence restricted to available loci was defined. Some of 
the short haplotypes are unique, and they can be matched with their corresponding 
haplogroup directly. However, most of the time, given the small number of SNPs analyzed, 
several haplogroups correspond to the same short haplotype. Consequently, a unique 
haplogroup cannot confidently be assigned to each short haplotype. Therefore, each short 
haplotype was assigned the most recent common ancestor of all the haplogroups that share 
the same short haplotype. Once this matching was done, short haplotypes were reconstructed 
in the same way for each individual in our dataset, and assigned the corresponding 
haplogroup. Accuracy of the method used was assessed by being applied on a set of 630 
mitochondrial genome sequences of known European and Caucasian haplogroups (See 
Additional file 3) 
Figure 1 Simplified representation of the phylogenic method used to infer haplogroups. a. 
Full-length haplotypic sequences are reconstructed at each node of the reference tree. b. 
Haplotypes are then restricted to available loci. Sequences of the same color are identical. c. 
Unique short haplotypes are matched directly with the corresponding haplogroup. d. 
Sequences matching with several haplogroups are associated to their Most Recent common 
Ancestor haplogroup. 
Association detection 
This phylogenetic approach is based on the identification of subclades in the reference 
phylogenetic tree of the mitochondrial genome differentially enriched for cases and 
unaffected controls compared with neighboring subclades. We used ALTree [38,39] to 
perform association testing. ALTree - Association detection and Localization of susceptibility 
sites using haplotype phylogenetic Trees – is an algorithm performing nested homogeneity 
tests comparing distributions of affected and unaffected individuals in the different clades of 
a given phylogenetic tree. The objective is to detect if some clades of a phylogenetic tree are 
more or less enriched in affected/unaffected individuals compared to the rest of tree. There 
are as many tests performed as levels in the phylogenetic tree. The p-value at each level of 
the tree is obtained by a permutation procedure in which 1000 permutations are performed: 
individual labels (‘affected’ or ‘unaffected’) are permutated 1000 times to see to what extent 
the observed distribution of affected/unaffected is different from a random distribution. A 
procedure to correct for multiple testing adapted to nested tests [40] is implemented in 
ALTree. The objective of ALTree is to detect an enrichment difference at the level of the 
whole tree. In order to keep computational time and resources only the most significant p-
value obtained for all tests performed on one tree is corrected. 
Handling genetic dependency 
ALTree performs homogeneity tests to detect differences in enrichment or depletion of 
affected or unaffected individuals between clades in the phylogenetic tree. This kind of test 
can only be performed on independent data. However because in the CIMBA dataset, some 
individuals belong to the same family, we constructed datasets with genetically independent 
data by randomly selecting one individual among all those belonging to the same family and 
sharing the same short haplotype. To take into account the full variability of our data, we 
resampled one thousand times. Results of the analyses pipeline are obtained for each 
resampling independently, and then averaged over the one thousand re-samplings to obtain 
final results. 
Character reconstruction at ancestral nodes 
Before the ALTree localization algorithm was launched, ancestral sequences were 
reconstructed at each internal tree node, i.e. short haplotypes were inferred with maximum 
likelihood at all nodes that were not leaves. We used the software PAML [41] to perform the 
reconstruction at ancestral nodes using a maximum likelihood method. The phylogeny model 
used was the General Time-Reversible model (GTR or REV). 
Localization of susceptibility sites 
ALTree also includes an algorithm to identify which sites are the most likely ones to be 
involved in the association detected. For each short haplotype observed, the ALTree add-on 
altree-add-S will add to the short haplotype sequence a supplementary character called S, 
which represents the disease status associated to this short haplotype: are individuals carrying 
this short haplotype more often affected or unaffected? S is calculated based on the affected 
and unaffected counts, the relative proportion of affected and unaffected in the whole dataset, 
and sensibility parameter ε. ε was set to its default value, which is 1. After S character 
computation, haplotypes including character S are reconstructed at ancestral nodes. 
Susceptibility site localization is achieved with ALTree by computing a correlated evolution 
index calculated between each change of each site and the changes of the character S, in the 
two possible directions of change. The site(s) whose evolution is the most correlated to the 
character S is the most likely susceptibility site. 
Selected subclades 
Analyses were carried out on the full evolutionary tree. However, the more haplogroups there 
are at each level, the less statistical power homogeneity tests have. Therefore analyses were 
also applied to subclades extracted from the tree. Subclades were defined using counts of 
individuals in each haplogroup of the clade in order to maximize statistical power. Chosen 
subclades and corresponding affected and unaffected counts are presented in . 
Statistical analysis 
We quantified the effect associated with enrichment discovered by applying ALTree by 
building a weighted Cox regression in which the outcome variable is the status (affected or 
non-affected) and the explicative variable is the inferred haplogroup. Analyses were stratified 
by country. Data were restricted to the clades of interest. The uncertainty in haplogroup 
inference was not taken into account in the model. The weighting method used takes into 
account breast cancer incidence rate as a function of age [42] and the gene containing the 
observed pathogenic mutation, i.e. BRCA1 or BRCA2. Familial dependency was handled by 
using a robust sandwich estimate of variance (R package survival, cluster() function). 
Results 
Haplogroup imputation 
In Additional file 4, absolute and relative frequencies are recapitulated for each haplogroup 
imputed in BRCA1 and BRCA2 mutation carriers. For BRCA1 mutation carriers, we 
reconstructed 489 distinct short haplotypes of 93 loci from the genotypes data. Only 162 of 
those 489 short haplotypes matched theoretical haplotypes reconstructed in the reference 
mitochondrial evolutionary tree. These 162 haplotypes represented 13315 / 14536 
individuals. Thus, 91.6% of BRCA1 mutation carriers were successfully assigned a 
haplogroup. For BRCA2 mutation carriers, we reconstructed 350 distinct short haplotypes of 
92 loci from our genotypes data. Only 139 of those 350 short haplotypes matched theoretical 
haplotypes reconstructed in the reference mitochondrial evolutionary tree. These 139 
haplotypes represented 6996 / 7678 individuals. Thus, 91.1% of BRCA2 mutation carriers 
were successfully assigned a haplogroup. Since more BRCA1 than BRCA2 mutation carriers 
were genotyped (14,536 vs. 7,678 individuals), we logically observe more distinct haplotypes 
in pop1 than in pop2 (489 vs. 350 haplotypes). 
Accuracy of the main haplogroup inference method used was estimate at 82%, and reached 
100% for haplogroups I, J, K, T, U, W, X. Given the set of SNPs we dispose of, our method 
has difficulties to differentiate between H and V haplogroups (See Additional file 3). 
Association results 
For both populations of BRCA1 or BRCA2 mutation carriers, and for the full tree as for all 
selected subclades (See Table 1), we extracted the mean corrected p-value for association 
testing over all resamplings performed (See Table 2). The only corrected p-value that 
remained significant was that obtained for subclade T (abbreviated T*) in the population of 
individuals of BRCA2 mutation carriers (p = 0.04). 
Table 1 Counts of participants in selected subclades 
Subclade BRCA1 mutation carriers BRCA2 mutation carriers 
U8 1458 863 
T 1243 651 
J 1270 630 
J1 1043 513 
H 3706 1967 
H1 582 337
U5 868 458 
X1’2’3 221 103 
K1a 608 364 
Table 2 Mean corrected p-value for association testing with ALTree 
Subclade pop1 corrected p-value pop2 corrected p-value
Full 0.830 0.681 
U8 0.146 0.626
T 0.285 0.040
J 0.718 0.112 
J1 0.621 0.150 
H 0.747 0.930 
H1 0.268 0.804 
U5 0.829 0.747
X1’2’3 0.416 0.629 
K1a 0.170 0.162 
The phylogenetic tree of subclade T (see Figure 2a) contains only three levels, thus only three 
tests were performed within this clade. Raw p-values were examined to determine at which 
level of the tree ALTree detects a difference of enrichment in affected/unaffectd individuals 
(see Table 3). Only the p-value associated with the test performed at the first level of the tree 
is significant. We looked more closely at the mean frequencies of affected and unaffected 
individuals in the tree at this level (see Figure 2b). In the T1a1 subclade, the mean count of 
affected and unaffected are 32 and 47, respectively. In the T2* subclade, we observed on 
average 217 and 148 affected and unaffected individuals, respectively, whereas in the T 
subclade, we observed on average 13 and 11 affected and unaffected individuals. Ranges 
observed for each of these values over the 1000 resamplings are represented in Figure 2b. 
Based on these observations, we conclude that subclade T1a1 depleted in affected carriers 
compared to the neighboring subclades T and T2. 
Figure 2 Phylogenetic tree of subclade T tested for association with ALTree. a. Phylogenetic 
tree of subclade T with all observed haplogroups. A homogeneity test is performed at each 
level of the tree. b. First level of phylogenetic tree of subclade T. Averaged counts, ranges, 
and proportion of affected and unaffected observed in resamplings are indicated below each 
subclade, respectively. T2* represents the entire subclade T2. 
Table 3 Non-corrected p-values by level of phylogenetic tree for subclade T in BRCA2 
mutation carriers 
Level Degrees of freedom Mean of non-corrected p-value
1 2 0.02141039 
2 6 0.14355900 
3 8 0.22249700 
Localization results 
We performed a localization analysis with ALTree. The correlated evolution index for all 
non-monomorphic sites observed in short haplotype sequences of subclade T are displayed in 
Additional file 5. The higher the correlated evolution index, the more likely it is that 
corresponding sites will be involved in the observed association. Three short haplotype sites - 
numbered 44, 57, and 72 and corresponding to SNPs T988C, G11812A/rs4154217, and 
G13708A/rs28359178 - are clearly distinguishing themselves, with correlation index values 
of 0.390, 0.324 and 0.318 respectively, whereas all other sites correlation index values ranged 
from −0.270 to −0.101. Table 4 shows details for these three loci. 
Table 4 Description of loci identified as potential susceptibility sites by ALTree 
Site SNP Name Position Direction of change Correlated evolution index Major Allele Minor Allele MAF in pop2
44 MitoT9900C 9899 T → C 0.390 T C 0.016 
57 rs41544217 11812 G → A 0.324 A G 0.071 
72 rs28359178 13708 G → A 0.318 G A 0.111 
Effect quantification 
The ALTree method is able to detect an association, but cannot to quantify the associated 
effect. We estimated the risk of breast cancer for individuals with the T1a1 haplogroup 
compared with individuals having another T subclade haplogroup in the population of 
BRCA2 mutation carriers with a more classical statistical method, a weighted Cox regression. 
We found a breast cancer HR = 0.55 (95% CI = 0.34-0.88, p-value = 0.014). We also tested 
Haplogroup T1a1 compared with other T* haplogroups and the H haplogroup (the main 
haplogroup in the general population), and found a breast cancer HR = 0.62 (95% CI = 0.40-
0.95, p-value = 0.03). 
Discussion 
We employed an original phylogenetic analytic method coupled with more classical 
molecular epidemiologic analyses in order to detect mitochondrial haplogroups differentially 
enriched for affected BRCA1/2 mutation carriers. We successfully inferred haplogroups for 
more than 90% of individuals in our dataset. After haplogroup imputation, the ALTree 
method identified T1a1 in the T clade as differentially enriched in affected BRCA2 mutation 
carriers, whereas no enrichment difference was found for BRCA1 mutation carriers. The T 
subclade is present in 4% of African populations compared to 11% in Caucasian and east-
European populations [43]. In our data, the T subclade represented 9.34% of BRCA1 
mutation carriers, and 9.30% of BRCA2 carriers. The ALTree method also identified three 
potential breast cancer susceptibility loci in mitochondrial genome. The main goal of using 
the phylogenetic method we used was to improve statistical power by regrouping subclades 
according to genetic considerations, in order to limit the number of tests performed, and to 
precisely quantify this number. ALTree identified 3 SNPs of interest. While the association 
we observed could possibly be driven by a single SNP, no difference was observed between 
multivariate and univariate cox models including the 3 SNPs identified by ALTree (data not 
shown). 
In this study, we investigated to what extent mitochondrial genome variability modified 
breast cancer risk in individuals carrying pathogenic mutations in BRCA1/2. A large 
proportion of breast cancer heritability still remains unexplained today [44]. Different 
methods exist to study genomic susceptibility to a disease, such as linkage analyses (which 
identified the BRCA1 and BRCA2 susceptibility genes) or Genome-Wide Association Studies 
(GWAS). However, classical linkage analysis cannot be applied to the haploid mitochondrial 
genome. Furthermore, commercial GWAS chips available do not adequately capture the 
majority of mitochondrial SNPs. A non-genome-wide and mitochondrial focused approach 
was required to explore how mitochondrial genome variability influences breast cancer risk. 
Here we have shown that BRCA2 mutation carriers representing the subclade T1a1 have 
between 30 and 50% less risk of breast cancer than those representing other clades which, if 
validated, is a clinically meaningful risk reduction and may influence choice of risk 
management strategies. 
The association we observed among BRCA2 but not BRCA1 mutation carriers may reveal a 
functional alteration that would be specific to mechanisms involving BRCA2-related BC. 
Today it is established that BRCA1- and BRCA2-associated breast cancers are not 
phenotypically identical. These two types of tumors do not harbor the same gene expression 
profiles or copy number alterations [45]. Breast cancer risk modifiers in BRCA1/2 mutation 
carriers have already been identified [46]. However, most of them are specific from one or 
the other type of mutation carried [47]. It is therefore not surprising that this observation is 
observed in BRCA2 mutation carriers only. 
Three main reasons could explain our inability to assign haplogroups to 9% of study 
participants. First, given the high mutation rate in the mitochondrial genome, observed 
combinations of mitochondrial SNPs might have appeared relatively recently in the general 
population, and the corresponding haplotypes might not yet be incorporated in PhyloTree. 
Secondly, only one genotyping error could lead to chimeric haplotypes that do not exist 
although, given the quality of our genotyping data, this is unlikely. Finally, the mitochondrial 
reference evolutionary tree PhyloTree is based on phylogeny reconstruction by parsimony, 
and for some subclades it might be suboptimal, especially for haplogroups relying on few 
mitochondrial sequences, as is the case for African haplogroups [48]. In case of uncertainty, 
the choice we made to assign the most recent common ancestor to the studied haplotype 
enables us to improve statistical power without introducing a bias in the detected association. 
For the association detected between T, T1* and T2* subclades, the haplogroup inference 
method used do not bias the counts of affected and unaffected individuals in these subclades. 
More details are presented in Additional file 6. Furthermore, based on the haplogroup 
inference with our method of 630 European and Caucasian mitochondrial genome sequences 
whose haplogroup is known, we successfully assigned the correct main and subhaplogroup of 
100% of sequences belonging to T, T2*, and T1a1* haplogroups. 
We quantified the effect corresponding to the detected association by using a more classical 
approach. We built a weighted Cox regression including inferred haplogroup as explicative 
variable. However, the uncertainty in haplogroup inference was not taken into account in this 
model. Nevertheless, based on haplogroup assignment and regrouping performed in clade T, 
affected and unaffected counts of individuals in this clade were not biased. 
With only 129 loci genotyped over the 16,569 nucleotides composing the mitochondrial 
genome, we certainly do not explore the full variability of mitochondrial haplotypes. A 
characterization of individual mitochondrial genomes would require more complete data 
acquisition methods to be used, e.g., next-generation sequencing. However, next-generation 
sequencing presents its own limits and challenges, because some regions of the mitochondrial 
genome are not easily mappable due to a high homology with the nuclear genome among 
other factors, and important bioinformatics treatment is necessary to overcome sequencing 
technology biases. Finally, even for a relatively short genome of ‘only’ 16569 bp, 
mitochondrial genome sequencing of more than 20,000 individuals would represent a major 
increase in cost relative to genotyping 129 SNPs. 
ALTree identified T9899C, G11812A/rs41544217, and G13708A/rs28359178 as three 
potential susceptibility sites for the discovered association (See Additional file 7). These 3 
polymorphisms are respectively located in the coding part of genes MT-CO3, MT-ND4, and 
MT-ND5. When looking at PhyloTree, T9899C seems to be involved in T1 subclade 
definition, whereas G13708A and A11812G are involved in T2 subclade definition. Whereas 
T98899C and G11821/rs41544217 are synonymous polymophisms, G10398A leads to a 
change of amino acid in the final protein (from Alanine to Threonine). These 2 synonymous 
polymophisms have never been described in a disease context in the literature. G13708A is 
also known for being a secondary mutation for Leber’s hereditary optic neuropathy (LHON) 
and multiple sclerosis [49]. Although the role of secondary mutations in LHON is still 
controversial, G13708A could be associated with impairment of the respiratory chain in this 
pathology. G13708A has also been described as a somatic mutation in a breast cancer tumor, 
whereas it was not present in adjacent normal tissue and in blood leucocytes [50]. A high 
proportion of mitochondrial somatic tumor specific variants are also known mitochondrial 
polymorphisms, which is consistent with the hypothesis that tumor cells are prone to acquire 
the same mutations that segregate into mitochondrial genome by selective adaptation when 
humans migrated out of Africa and were confronted to new environments [51]. Interestingly, 
the germline variant G13708A has already been shown to be inversely associated with 
familial breast cancer risk (with the same direction of the association), with a breast cancer 
odds-ratio (OR) = 0.47 (95% CI = 0.24–0.92) [52]. None of these SNPs have been described 
in the context of ovarian cancer. 
The corrected p-value ALTree obtained in studying clade T is 0.02, which not highly 
significant. A replication step should be performed to validate these results. However, it will 
be difficult to include enough women in this replication step, given the specific profile 
studied here. In fact, the estimations of BRCA2 pathogenic mutations in the general 
population range from 0.068% [5] to 0.69% [53]. T1a1 represents sonly a small percentage of 
European haplogroups (from 1% to 2%). The number of women concerned by this 
association is therefore low. However, women carrying such mutations are confronted with 
drastic choices regarding the prevention of breast cancer, notably prophylactic mastectomy or 
complete hysterectomy. If breast cancer risk is really reduced by 2 for T1a1 women, this 
could be an important fact to take into account for breast cancer prevention. 
Conclusions 
This and our results suggest that mitochondrial haplogroups T1a1 may modify the individual 
breast cancer risk in BRCA2 mutation carriers. For now, this observation cannot be extended 
to the general population. Further investigation of the biological mechanism behind the 
associations we observed may further reinforce the hypothesis that the mitochondrial genome 
is influential in breast cancer. risk, particularly among carriers of BRCA2 mutations and, if 
validated, is of a level to influence cancer risk management choices. 
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